Invox Pharma Limited

Maxion Therapeutics Limited

Iontas Limited

Sachin Badrinath Surade

Francisca Wollerton

Matthew Lakins

Tim Luetkens

John Mccafferty

Aneesh Karatt Vellatt

Edward William Masters

Damian Colin Bell

Mateusz Wydro

Michael Dyson

The present disclosure, in some aspects, provides antibody molecules, or antigen-binding fragments thereof capable of binding specifically to PD-L1. The present disclosure further provides antibody molecules, or antigen-binding fragments thereof capable of binding specifically to PD-L1 and a second antigen-binding site. Methods of making and/or using such antibody molecules or antigen bending fragments are also provided.

Antibody molecules

Binding members for sodium channel Nav1.7 and their use in medicine including for treatment of pain or epilepsy. Binding members comprise a fusion protein containing a Nav1.7-binding peptide, e.g., venom toxin peptide or knottin ('donor diversity scaffold domain') inserted within an antibody variable domain (“recipient diversity scaffold domain”), and a partner domain (e.g., antibody variable domain), optionally wherein the partner domain enhances specificity of binding to Nav1.7 over other sodium channels.

Sodium channel inhibitors

Growing community of inventors

Sawston, United Kingdom

Sachin Badrinath Surade